Neel Butala
Concepts (231)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Transcatheter Aortic Valve Replacement | 17 | 2025 | 153 | 8.230 |
Why?
| | Aortic Valve Stenosis | 13 | 2025 | 255 | 6.460 |
Why?
| | Percutaneous Coronary Intervention | 23 | 2025 | 550 | 4.860 |
Why?
| | Embolic Protection Devices | 4 | 2024 | 12 | 2.370 |
Why?
| | Administrative Claims, Healthcare | 4 | 2025 | 29 | 1.860 |
Why?
| | Heart Valve Prosthesis Implantation | 6 | 2025 | 197 | 1.680 |
Why?
| | Stroke | 10 | 2025 | 1287 | 1.640 |
Why?
| | Coronary Artery Disease | 6 | 2023 | 751 | 1.630 |
Why?
| | Registries | 16 | 2026 | 2400 | 1.600 |
Why?
| | Medicare | 16 | 2025 | 920 | 1.560 |
Why?
| | Myocardial Infarction | 10 | 2025 | 1215 | 1.480 |
Why?
| | Aortic Valve | 7 | 2025 | 360 | 1.450 |
Why?
| | Treatment Outcome | 32 | 2026 | 11821 | 1.360 |
Why?
| | Data Accuracy | 3 | 2024 | 64 | 1.140 |
Why?
| | Risk Factors | 24 | 2025 | 10921 | 1.110 |
Why?
| | ST Elevation Myocardial Infarction | 4 | 2021 | 65 | 1.070 |
Why?
| | Platelet Aggregation Inhibitors | 7 | 2023 | 499 | 1.050 |
Why?
| | Insurance Claim Review | 2 | 2025 | 87 | 1.050 |
Why?
| | Patient Readmission | 7 | 2020 | 778 | 1.030 |
Why?
| | United States | 35 | 2026 | 16136 | 1.000 |
Why?
| | Directories as Topic | 2 | 2024 | 6 | 0.970 |
Why?
| | Risk Assessment | 10 | 2025 | 3712 | 0.960 |
Why?
| | Insurance Carriers | 2 | 2024 | 14 | 0.960 |
Why?
| | Hospitals | 5 | 2023 | 738 | 0.960 |
Why?
| | Postoperative Complications | 5 | 2025 | 3034 | 0.930 |
Why?
| | Hospital Mortality | 7 | 2024 | 1051 | 0.920 |
Why?
| | Aged | 38 | 2026 | 26432 | 0.920 |
Why?
| | Aged, 80 and over | 19 | 2026 | 8391 | 0.870 |
Why?
| | Physicians | 2 | 2024 | 955 | 0.850 |
Why?
| | Mitral Valve | 3 | 2026 | 96 | 0.850 |
Why?
| | Endpoint Determination | 1 | 2025 | 84 | 0.830 |
Why?
| | Patient Discharge | 6 | 2025 | 997 | 0.800 |
Why?
| | Atherectomy, Coronary | 1 | 2023 | 10 | 0.790 |
Why?
| | Time Factors | 14 | 2025 | 7109 | 0.790 |
Why?
| | Insurance, Health | 2 | 2024 | 318 | 0.780 |
Why?
| | Shock, Cardiogenic | 1 | 2023 | 65 | 0.750 |
Why?
| | Heart Valve Prosthesis | 2 | 2021 | 127 | 0.750 |
Why?
| | Longevity | 1 | 2024 | 179 | 0.750 |
Why?
| | Mortality | 3 | 2018 | 375 | 0.730 |
Why?
| | Postoperative Hemorrhage | 2 | 2021 | 106 | 0.720 |
Why?
| | Coronary Occlusion | 1 | 2022 | 20 | 0.720 |
Why?
| | Vascular Calcification | 1 | 2023 | 109 | 0.710 |
Why?
| | Humans | 65 | 2026 | 146342 | 0.710 |
Why?
| | Intensive Care Units | 3 | 2025 | 925 | 0.700 |
Why?
| | Frailty | 2 | 2023 | 208 | 0.690 |
Why?
| | Diabetes Mellitus | 3 | 2015 | 1101 | 0.690 |
Why?
| | Surgical Procedures, Operative | 1 | 2025 | 307 | 0.680 |
Why?
| | Preventive Health Services | 2 | 2013 | 154 | 0.650 |
Why?
| | Anticoagulants | 3 | 2021 | 746 | 0.620 |
Why?
| | Data Collection | 1 | 2023 | 650 | 0.610 |
Why?
| | Clinical Trials as Topic | 4 | 2023 | 1064 | 0.600 |
Why?
| | Severity of Illness Index | 2 | 2025 | 2921 | 0.590 |
Why?
| | Data Mining | 1 | 2020 | 113 | 0.590 |
Why?
| | Databases, Factual | 6 | 2025 | 1493 | 0.580 |
Why?
| | Anesthesia, General | 1 | 2020 | 124 | 0.580 |
Why?
| | Endovascular Procedures | 1 | 2023 | 390 | 0.560 |
Why?
| | Incidence | 8 | 2025 | 2936 | 0.540 |
Why?
| | Clinical Decision-Making | 1 | 2021 | 365 | 0.540 |
Why?
| | Economics, Hospital | 1 | 2018 | 29 | 0.530 |
Why?
| | Kidney Transplantation | 2 | 2015 | 735 | 0.520 |
Why?
| | Students, Medical | 2 | 2013 | 383 | 0.520 |
Why?
| | Betacoronavirus | 1 | 2020 | 288 | 0.520 |
Why?
| | Peripheral Arterial Disease | 2 | 2023 | 507 | 0.520 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2018 | 97 | 0.510 |
Why?
| | Stents | 2 | 2021 | 554 | 0.510 |
Why?
| | Practice Patterns, Physicians' | 3 | 2021 | 1408 | 0.490 |
Why?
| | Occupational Exposure | 1 | 2020 | 356 | 0.490 |
Why?
| | Quality of Health Care | 3 | 2016 | 702 | 0.480 |
Why?
| | Male | 36 | 2026 | 73396 | 0.480 |
Why?
| | Coronary Angiography | 3 | 2023 | 325 | 0.460 |
Why?
| | Female | 35 | 2026 | 79499 | 0.450 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 387 | 0.450 |
Why?
| | Coronavirus Infections | 1 | 2020 | 379 | 0.450 |
Why?
| | Retrospective Studies | 12 | 2025 | 17438 | 0.440 |
Why?
| | Pneumonia | 2 | 2018 | 635 | 0.430 |
Why?
| | Seasons | 1 | 2017 | 540 | 0.430 |
Why?
| | Angina Pectoris | 3 | 2022 | 76 | 0.420 |
Why?
| | Academic Medical Centers | 2 | 2015 | 561 | 0.420 |
Why?
| | Health Personnel | 1 | 2020 | 754 | 0.400 |
Why?
| | Waiting Lists | 1 | 2015 | 251 | 0.390 |
Why?
| | Mitral Valve Insufficiency | 2 | 2026 | 69 | 0.390 |
Why?
| | Healthcare Disparities | 1 | 2020 | 733 | 0.380 |
Why?
| | Graft Survival | 1 | 2015 | 523 | 0.380 |
Why?
| | Delayed Graft Function | 1 | 2013 | 56 | 0.370 |
Why?
| | Intracranial Embolism | 2 | 2024 | 34 | 0.370 |
Why?
| | Tissue Donors | 1 | 2015 | 425 | 0.360 |
Why?
| | Income | 2 | 2022 | 206 | 0.350 |
Why?
| | Tissue and Organ Procurement | 1 | 2015 | 305 | 0.350 |
Why?
| | Middle Aged | 19 | 2025 | 36619 | 0.350 |
Why?
| | Community Health Centers | 1 | 2012 | 59 | 0.340 |
Why?
| | Hospitalization | 5 | 2026 | 2475 | 0.340 |
Why?
| | Ambulatory Care Facilities | 1 | 2013 | 269 | 0.330 |
Why?
| | Predictive Value of Tests | 3 | 2025 | 2113 | 0.320 |
Why?
| | Disease Management | 1 | 2015 | 651 | 0.320 |
Why?
| | Urban Renewal | 1 | 2010 | 5 | 0.320 |
Why?
| | Odds Ratio | 5 | 2021 | 1077 | 0.320 |
Why?
| | Poverty Areas | 1 | 2010 | 43 | 0.310 |
Why?
| | Urban Health | 1 | 2010 | 95 | 0.310 |
Why?
| | Sanitation | 1 | 2010 | 56 | 0.300 |
Why?
| | Ambulatory Care | 1 | 2015 | 628 | 0.300 |
Why?
| | Ischemic Attack, Transient | 2 | 2021 | 71 | 0.300 |
Why?
| | Communicable Disease Control | 1 | 2010 | 88 | 0.300 |
Why?
| | Water Supply | 1 | 2010 | 90 | 0.300 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 144 | 0.290 |
Why?
| | Quality Improvement | 2 | 2018 | 1354 | 0.280 |
Why?
| | Heart Failure | 3 | 2026 | 2329 | 0.270 |
Why?
| | Propensity Score | 4 | 2025 | 376 | 0.250 |
Why?
| | Mass Screening | 2 | 2013 | 1307 | 0.250 |
Why?
| | Sex Characteristics | 2 | 2014 | 801 | 0.250 |
Why?
| | Chronic Disease | 2 | 2023 | 1827 | 0.240 |
Why?
| | Reproducibility of Results | 3 | 2025 | 3416 | 0.240 |
Why?
| | Cardiac Catheterization | 3 | 2026 | 571 | 0.240 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2025 | 1763 | 0.230 |
Why?
| | Life Expectancy | 2 | 2016 | 72 | 0.230 |
Why?
| | Delivery of Health Care | 2 | 2018 | 947 | 0.210 |
Why?
| | Fee-for-Service Plans | 1 | 2025 | 98 | 0.210 |
Why?
| | Drug Therapy, Combination | 3 | 2023 | 1036 | 0.210 |
Why?
| | Blood Glucose | 1 | 2015 | 2360 | 0.210 |
Why?
| | Medicare Part C | 1 | 2025 | 39 | 0.210 |
Why?
| | Protective Factors | 1 | 2024 | 97 | 0.200 |
Why?
| | Limb Salvage | 1 | 2023 | 74 | 0.190 |
Why?
| | Purinergic P2Y Receptor Antagonists | 2 | 2023 | 71 | 0.190 |
Why?
| | Connecticut | 2 | 2014 | 25 | 0.190 |
Why?
| | Community Health Services | 1 | 2025 | 229 | 0.190 |
Why?
| | Specialization | 1 | 2024 | 137 | 0.190 |
Why?
| | Primary Health Care | 1 | 2013 | 1776 | 0.190 |
Why?
| | Chest Pain | 2 | 2020 | 100 | 0.180 |
Why?
| | Disability Evaluation | 1 | 2024 | 297 | 0.180 |
Why?
| | Medicine | 1 | 2024 | 127 | 0.180 |
Why?
| | Nitroglycerin | 1 | 2022 | 14 | 0.180 |
Why?
| | Cross-Sectional Studies | 5 | 2022 | 5899 | 0.180 |
Why?
| | Echocardiography | 1 | 2025 | 645 | 0.180 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2025 | 305 | 0.170 |
Why?
| | Follow-Up Studies | 4 | 2021 | 5439 | 0.170 |
Why?
| | Cardiovascular Diseases | 2 | 2025 | 2219 | 0.170 |
Why?
| | Coronary Stenosis | 1 | 2021 | 40 | 0.160 |
Why?
| | Glycyrrhiza | 1 | 2020 | 3 | 0.160 |
Why?
| | Glycyrrhetinic Acid | 1 | 2020 | 7 | 0.160 |
Why?
| | Mineralocorticoids | 1 | 2020 | 7 | 0.160 |
Why?
| | United States Department of Veterans Affairs | 1 | 2025 | 777 | 0.160 |
Why?
| | Hyperaldosteronism | 1 | 2020 | 12 | 0.160 |
Why?
| | Ischemia | 1 | 2023 | 421 | 0.160 |
Why?
| | Receptors, Purinergic P2Y12 | 1 | 2020 | 6 | 0.160 |
Why?
| | Bioprosthesis | 1 | 2020 | 39 | 0.160 |
Why?
| | Cardiology Service, Hospital | 1 | 2020 | 29 | 0.150 |
Why?
| | Cardiologists | 1 | 2020 | 45 | 0.150 |
Why?
| | International Classification of Diseases | 1 | 2020 | 142 | 0.150 |
Why?
| | Sex Factors | 1 | 2025 | 2107 | 0.140 |
Why?
| | Drug Utilization | 1 | 2020 | 171 | 0.140 |
Why?
| | Thrombosis | 2 | 2020 | 398 | 0.140 |
Why?
| | Death, Sudden, Cardiac | 1 | 2020 | 242 | 0.140 |
Why?
| | Risk | 1 | 2020 | 920 | 0.130 |
Why?
| | Guidelines as Topic | 1 | 2020 | 267 | 0.130 |
Why?
| | Health Services Research | 1 | 2020 | 390 | 0.130 |
Why?
| | Acute Kidney Injury | 1 | 2025 | 866 | 0.130 |
Why?
| | Adult | 7 | 2023 | 41087 | 0.130 |
Why?
| | Calcium | 1 | 2023 | 1181 | 0.130 |
Why?
| | New York | 1 | 2017 | 128 | 0.130 |
Why?
| | Quality Indicators, Health Care | 1 | 2020 | 343 | 0.120 |
Why?
| | Outpatients | 1 | 2020 | 440 | 0.120 |
Why?
| | Practice Guidelines as Topic | 2 | 2016 | 1591 | 0.120 |
Why?
| | Decision Support Techniques | 1 | 2020 | 478 | 0.120 |
Why?
| | Brain Ischemia | 1 | 2019 | 362 | 0.110 |
Why?
| | California | 1 | 2017 | 475 | 0.110 |
Why?
| | Elective Surgical Procedures | 1 | 2017 | 216 | 0.110 |
Why?
| | Medicaid | 1 | 2020 | 477 | 0.110 |
Why?
| | Young Adult | 5 | 2022 | 14330 | 0.110 |
Why?
| | Glycemic Index | 1 | 2015 | 26 | 0.110 |
Why?
| | Disease Progression | 1 | 2022 | 2867 | 0.100 |
Why?
| | Cold Ischemia | 1 | 2013 | 39 | 0.090 |
Why?
| | Physical Examination | 1 | 2013 | 237 | 0.090 |
Why?
| | Venous Thromboembolism | 1 | 2016 | 332 | 0.090 |
Why?
| | Prognosis | 1 | 2021 | 4351 | 0.090 |
Why?
| | Egypt | 1 | 2011 | 13 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1707 | 0.090 |
Why?
| | Guideline Adherence | 1 | 2016 | 594 | 0.090 |
Why?
| | Medically Uninsured | 1 | 2012 | 134 | 0.080 |
Why?
| | Hemorrhage | 3 | 2023 | 825 | 0.080 |
Why?
| | Linear Models | 1 | 2013 | 857 | 0.080 |
Why?
| | Atrial Fibrillation | 1 | 2016 | 560 | 0.080 |
Why?
| | Policy Making | 1 | 2010 | 83 | 0.080 |
Why?
| | India | 1 | 2010 | 213 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2013 | 1543 | 0.070 |
Why?
| | Communicable Diseases | 1 | 2010 | 166 | 0.070 |
Why?
| | Regression Analysis | 1 | 2010 | 999 | 0.070 |
Why?
| | Health Policy | 1 | 2010 | 399 | 0.060 |
Why?
| | Aspirin | 2 | 2023 | 405 | 0.060 |
Why?
| | Comorbidity | 2 | 2025 | 1665 | 0.060 |
Why?
| | Logistic Models | 2 | 2021 | 2126 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2017 | 2623 | 0.050 |
Why?
| | Length of Stay | 2 | 2018 | 1358 | 0.040 |
Why?
| | Coronary Artery Bypass | 1 | 2023 | 269 | 0.040 |
Why?
| | Aldosterone | 1 | 2020 | 42 | 0.040 |
Why?
| | Drug-Eluting Stents | 1 | 2021 | 88 | 0.040 |
Why?
| | Hypokalemia | 1 | 2020 | 23 | 0.040 |
Why?
| | Ventricular Fibrillation | 1 | 2020 | 63 | 0.040 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2017 | 3930 | 0.040 |
Why?
| | Nutrition Surveys | 1 | 2022 | 270 | 0.040 |
Why?
| | Prasugrel Hydrochloride | 1 | 2020 | 22 | 0.040 |
Why?
| | Blood Chemical Analysis | 1 | 2020 | 109 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2020 | 302 | 0.040 |
Why?
| | Skilled Nursing Facilities | 1 | 2021 | 152 | 0.040 |
Why?
| | Cause of Death | 1 | 2021 | 456 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2025 | 881 | 0.040 |
Why?
| | Health Care Surveys | 1 | 2020 | 541 | 0.030 |
Why?
| | Hydrocortisone | 1 | 2020 | 303 | 0.030 |
Why?
| | Algorithms | 1 | 2025 | 1849 | 0.030 |
Why?
| | Electroencephalography | 1 | 2020 | 576 | 0.030 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2020 | 334 | 0.030 |
Why?
| | Dabigatran | 1 | 2016 | 30 | 0.030 |
Why?
| | Postoperative Period | 1 | 2017 | 355 | 0.030 |
Why?
| | Child, Preschool | 2 | 2023 | 11913 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1503 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 872 | 0.030 |
Why?
| | Warfarin | 1 | 2016 | 179 | 0.030 |
Why?
| | Thrombolytic Therapy | 1 | 2016 | 165 | 0.030 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2016 | 253 | 0.030 |
Why?
| | Pyridones | 1 | 2016 | 210 | 0.030 |
Why?
| | Rivaroxaban | 1 | 2016 | 270 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 970 | 0.030 |
Why?
| | Time-to-Treatment | 1 | 2016 | 257 | 0.020 |
Why?
| | Survival Analysis | 1 | 2016 | 1378 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2016 | 1331 | 0.020 |
Why?
| | Pyrazoles | 1 | 2016 | 517 | 0.020 |
Why?
| | Age Factors | 1 | 2020 | 3347 | 0.020 |
Why?
| | Adolescent | 2 | 2022 | 22557 | 0.020 |
Why?
| | Child | 2 | 2022 | 22693 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2020 | 2786 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 6460 | 0.020 |
Why?
| | Infant | 1 | 2020 | 10114 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 6073 | 0.010 |
Why?
|
|
Butala's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|